5-异丙基-5-苯基乙内酰脲 | 6634-13-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 5-异丙基-5-苯基乙内酰脲
• 英文名称: 5-isopropyl-5-phenylhydantoin
• 英文别名: 5-isopropyl-5-phenyl-imidazolidine-2,4-dione；5-Isopropyl-5-phenyl-imidazolidin-2,4-dion；5-Isopropyl-5-phenylimidazolidine-2,4-dione；5-phenyl-5-propan-2-ylimidazolidine-2,4-dione
• CAS: 6634-13-5
• 化学式: C₁₂H₁₄N₂O₂
• mdl: MFCD00068878
• 分子量: 218.255
• InChiKey: QMVMUGBHMIUWDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-异丙基-5-苯基乙内酰脲 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 18.0h， 以50%的产率得到2-amino-3-methyl-2-phenyl-butyric acid
  参考文献：
  名称：

  WO2007/58601

  摘要：

  公开号：
• 作为产物：
  描述：

  异丙基-苯基-丙二腈 在 次溴酸钾 作用下， 生成 5-异丙基-5-苯基乙内酰脲
  参考文献：
  名称：

  DE335994

  摘要：

  公开号：

文献信息

• Synthesis, structure, and solvatochromic properties of pharmacologically active 5-substituted 5-phenylhydantoins
  作者：Nemanja Trišović、Nataša Valentić、Marko Erović、Tatjana Đaković-Sekulić、Gordana Ušćumlić、Ivan Juranić

  DOI：10.1007/s00706-011-0639-7

  日期：2011.12

  200–400 nm in selected solvents of different polarity. The effects of solvent dipolarity/polarizability and solvent–solute hydrogen-bonding interactions were analyzed by means of the linear solvation energy relationship concept proposed by Kamlet and Taft. The lipophilicities of the investigated hydantoins were estimated by calculation of their log P values. The quantitative relationship between the ratio

  摘要合成了一系列5-取代的5-苯基乙内酰脲，并在不同极性的选定溶剂中于200-400 nm范围内记录了它们的紫外吸收光谱。借助Kamlet和Taft提出的线性溶剂化能量关系概念，分析了溶剂的偶极/极化性和溶剂-溶质氢键相互作用的影响。通过计算它们的log P值来估计所研究的乙内酰脲的亲脂性 。讨论了特定溶剂相互作用的贡献比与相应的亲脂性参数之间的定量关系。相关方程式与相应的ED 50组合值和不同的理化参数来生成新的方程式，以证明溶质-溶剂相互作用与结构-活性参数之间的合理关系。为了确定不同溶剂中吸收带的光谱分配，进行了量子化学计算。 图形概要
• Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
  申请人：Albert Jeffrey

  公开号：US20090176850A1

  公开（公告）日：2009-07-09

  This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及具有下面的结构式I的新化合物及其药学上可接受的盐、组合物和使用方法。这些新化合物可用于治疗或预防认知障碍、阿尔茨海默病、神经退行性疾病和痴呆症。
• Synthesis, structural and biological characterization of 5-phenylhydantoin derivatives as potential anticonvulsant agents
  作者：Nemanja Trišović、Tamara Timić、Jovana Divljaković、Jelena Rogan、Dejan Poleti、Miroslav M. Savić、Gordana Ušćumlić

  DOI：10.1007/s00706-012-0791-8

  日期：2012.10

  Considering the importance of hydantoin derivatives in treatment of status epilepticus, four 5-phenylhydantoins, whose lipophilicities were estimated to be similar to that of phenytoin, were synthesized. Evaluation of their anticonvulsant activities was performed on rats by subcutaneous pentylenetetrazol seizure test and intravenous pentylenetetrazol threshold test, and spontaneous locomotor activity test was used to assess possible sedative effects. X-ray analysis of three compounds suggested that certain analogies might be drawn between interactions in crystal packing and biological interactions responsible for their anticonvulsant activity. It was found that 5-ethyl-5-phenyl-3-propylhydantoin exhibits the most favorable pharmacological properties among the synthesized compounds, i.e., anticonvulsant activity comparable to phenytoin with lower liability for induction of sedation in rats.
• NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER S DISEASE, NEURODEGENERATION AND DEMENTIA
  申请人：Astra Zeneca AB

  公开号：EP1954682A1

  公开（公告）日：2008-08-13
• [EN] NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA<br/>[FR] NOUVEAUX COMPOSES 2-AMINO-IMIDAZOLE-4-ONE ET LEUR UTILISATION DANS LA FABRICATION D'UN MEDICAMENT DESTINE A ETRE UTILISE DANS LE TRAITEMENT D'UNE DEFICIENCE COGNITIVE, LA MALADIE D'ALZHEIMER, LE NEURODEGENERESCENCE ET LA DEMENCE
  申请人：ASTRAZENECA AB

  公开号：WO2007058601A1

  公开（公告）日：2007-05-24

  [EN] This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
  [FR] L'invention concerne de nouveaux composés présentant de formule structurelle (I) et leurs sels pharmaceutiquement acceptables, leurs compositions et leurs procédés d'utilisation. Les nouveaux composés de l'invention sont utilisés dans le traitement ou la prophylaxie d'une déficience cognitive, de la maladie d'Alzheimer, de la neurodégénerescence et de la démence.